In case you missed it: August 16 to August 20
It was a busy week for the Contemporary OB/GYN team.
This week's top articles included:
FDA accepts pembrolizumab as single agent for treatment of advanced endometrial cancer
The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
New biomarker could predict immunotherapy benefit in breast cancer
The Major Histocompatibility Complex Class II protein has potential to predict immunotherapy benefit in two types of breast cancer.
Hormonal intravaginal rings could facilitate combination therapies for several conditions
“Topical drug delivery also provides higher concentrations of the drug to the target site and has fewer side effects,” wrote the authors.
New Hampshire's abortion restrictions
We spoke with Editorial Board member Ilana Cass, MD, about her opinion of her state's latest abortion restrictions.
Study shows a healthy prenatal diet could be upstream obesity prevention strategy
December 26th 2024"Our findings support the recommendation of a healthy diet based on the current guidelines (as measured by the HEI) during pregnancy, since it may reduce patterns of infant growth outside reference ranges."
Read More
Midlife sexual health boosts for nonheterosexual women reported
December 23rd 2024A recent study highlights improved sexual function and reduced distress among nonheterosexual women during menopause compared to their heterosexual counterparts, shedding light on how sexual identity impacts well-being.
Read More
